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• A number of recent publications have shown that 
secondary prevention of cerebrovascular ischemic brain 
events is possible with anti-aggregating drugs. Comparison 
between the different studies is difficult, but the results 
obtained with using a combination therapy with aspirin 
(ASA) and dipyridamole (DP) seem to be superior to the 
results obtained with ASA alone. The first European Stroke 
Prevention Study (ESPS 1), that used 990 mgASA and 225 
mg DP a day, showed this clearly. In an attempt to minimise 
the side efects of a large dose ASA and possibly even to 
improve the efficacy, ESPS 2 was established. ESPS 2 will 
compare 50 mgASA, 400 mgDP, the combination of both, 
and placebo. 
ASPIRIN VERSUS ASPIRIN+DIPYRIDAMOLE 
• Possible superiority of secondary prevention using 
a combination of ASA with DP has already been men- 
tioned by FitzGerald (1) and can be confirmed by com- 
paring the four main studies of secondary prevention after 
an ischemic lesion of the nervous system. Among the main 
studies we accepted only those that have included more 
than 1000 patients. They are the United Kingdom Transient 
Ischemic Attack (UK-TIA) Study (2), the Canadian 
American Ticlopidine Study (CATS) (3), the Swedish 
Aspirin Low Dose Trial (SALT) (4) and the first European 
Stroke Prevention Study (ESPS 1) (5). Even if these four 
studies differ in many respects from each other, the risk 
reductions for similar endpoints are comparable. For the 
two common endpoints (stroke/myocardial infarction or 
death and vascular death), the best risk reduction was 
achieved with the combination of ASA and DP 
(ASA+DP) (Table 1). About the vascular death, 
ASA+DP and ticlopidine had efficacy. 
Table 1. 
Comparison of risk reduction (%) of similar endpoints in the 
four main studies of secondary prevention of cerebrovascular 
 
Endpoint        ESPS 15  UK-TIA2       CATS3               SALT4 
    
 Study      Study    Study 
                         (ASA)       (ASA)     (Ticlopidine)   (ASA) 
 
Stroke               33                    16                      17                      14 
+myocardial 
infarction + death 
Vascular                     26                 5                   22                    8 
death 
To demonstrate the possible significant differences 
between the treatment regimens, we underwent a meta- 
analysis of seven studies that have used ASA vs. placebo 
and two studies using ASA+DP vs. placebo (6). The effi- 
cacy of the treatment was analysed using five endpoints 
(all strokes, fatal strokes, important vascular events, all 
deaths, vascular deaths). The risk reduction was found only 
in three of them in the studies using ASA alone (all deaths, 




AS A+DP, risk reduction was found in all five endpoints 
analysed. In addition, risk reduction was always higher in 
the ASA+DP group. The difference in risk reduction 
between the two series was statistically significant in three 
of the analysed endpoints (all strokes, fatal strokes, impor- 
tant vascular events), but it was not significant in all deaths 
and vascular deaths. 
The efficacy of the combination therapy used in ESPS 1 
is well documented. What is then the reason to organize a 
second European Stroke Prevention Study (ESPS 2)? 
THE REASONS TO ESTABLISH ESPS 2 
• There is a demonstrable significant difference in 
the main results in ESPS 1 between intention-to-treat 
analysis and explanatory analysis (Table 2). Intention-to- 
treat analysis takes into account results in all randomized 
patients, and explanatory analysis was based only on results 
in patients who were eligible and complied with the pro- 
tocol. Even if the difference between these two types of 
analyses is not remarkable, it would be desirable to mini- 
mize the differences between intention-to-treat and 
explanatory analyses. 
Table 2. 
Risk reduction of ischemia events in the European Stroke 
Prevention Study J (All patients, stroke or death from any rea- 
son as the endpoint). 
Most of the adverse events were equally distributed 
between the two treatment groups. Some were, however 
significantly increased in the active treatment group (Table 
3), and most probably were due to the influence of ASA. 
Among the most important ones are the bleedings. The 
information about bleedings, coming from different ASA 
studies in comparison with placebo, shows that they are 
twice as frequent in the treatment group as in the place- 
bo group (Table 4). The bleedings may reach even 7 to 8 
%, twice as much in the active than the placebo group. 
The bleedings are probably dose dependent (7, 8). 
Reducing the dosage of ASA could improve the results of 
the treatment by decreasing the incidence of the side 
effects. 
Table 3. 





The drop-outs in ESPS 1 reached 34 % in the treatment 
group, but only 30 % in the placebo group, which differ- 
ence is statistically significant. Some of the interruptions 
of the treatment were due to non-medical reasons, some 
to intercurrent diseases. However, in more than 40 % of 
the patients with ASA+DP in whom the treatment was 
stopped, it was due to the side effects. In the placebo group, 
the cessation for this reason was necessary only in 27 % 
of the patients. 
Table 4. 
Frequency of bleedings in aspirin studies (%). 
 
Thus, the main reasons to organize a new study (ESPS 2) 
are: 1) To test, whether the risk reduction observed in ESPS 
1 can be achieved with a lower dose of ASA, thereby pre- 
venting the high incidence of ASA-related adverse effects 
seen in the first trial, 2) to test, whether ASA or DP given 
alone, rather than in combination, can achieve a signifi-   
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cant reduction in cerebrovascular events, 3) to improve 
and computerize the data collection and handling. We 
hope with the new methodology to minimize the differ- 
ences between intention-to-treat and explanatory analysis. 
THE METHODOLOGICAL IMPROVEMENTS IN 
ESPS 2 
• Since ESPS 1 was organized in 1977 and ESPS 2 
ten years later, one can understand that in ESPS 2 more 
computerized methods are used. The computerization 
allows the usage of a completely automated study design 
(Fig. 1). The patients are recruited in one of the 55 cen- 
tres that are connected to the randomization centre by 
computer. The trialist has to answer to more than 20 ques- 
tions in case of a new possible patient aimed to be recruit- 
ed to the study, and send this information by computer to 
the European Organization for Research and Treatment 
of Cancer (EORTC) in Brussels. If a patient is accepted 
to the study, the answer is sent to the clinical trialist, to the 
sample supply centre and to the statistical centre. All infor- 
mation issued from the randomization or the follow-up 
visits of the patients is sent later to the Coordinating 
Committee. The Coordinating Committee informs all the 
other committees including the Steering Committee, the 
ESPS2 ORGANIZATION 
Figure 1. 
Flowchart of the European Stroke Prevention Study 2. 
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Ethics Committee and the Protocol and Publishing com- 
mittee. The Coordinating Committee works with two sub- 
committees: the Technical Support Unit (TSU) and the 
Morbidity and Mortality Assessment Group (MMAG). 
HOW TO DIMINISH THE SIDE EFFECTS OF 
ASA? 
• It was decided that the ESPS 2 will have four arms: 
placebo, ASA 50 mg a day, DP 400 mg a day and ASA 
50 mg+DP 400 a day. The usage of 50 mg of ASA was 
accepted due to the modern view favouring low-dose 
aspirin. Aspirin inhibits the synthesis of thromboxane A2 
in platelets by irreversibly acetylating the active site of 
cyclooxygenase while simultaneously inhibiting the pro- 
duction of prostacyclin. To avoid this "aspirin dilemma", 
low doses of aspirin are now widely recommended based 
on the assumption that a low dose can inhibit thrombox- 
ane synthesis in platelets with much less effect on prosta- 
cyclin production in vascular endothelium. 
There are controversial opinions of using a placebo group 
in studies of secondary prevention of stroke. It is impos- 
sible to perform a study like ESPS 2 without having a con- 
trol group. One option would have been to take ASA alone 
as the control group. However, ASA cannot be used as a 
control because of great variability in the efficacy obtained 
in different studies. The risk reductions vary in these stud- 
ies from 9 % to 43 % (Table 5). This discrepancy has been 
observed by other authors (15,16) as shown in the con- 
clusion of the publication of the UK TIA Study (2) was: 
"however, on balance, the effect of aspirin is likely to be 
favourable...". The side effects of ASA are an other rea- 
son for not accepting it as a placebo. The ignorance regard- 
ing the best dose of ASA in cerebrovascular diseases (17) 
is also a reason not to use it as a control. It would be non- 
ethical by refusing the placebo not to collect the proper 
information necessary, to later on protect more patients 
from new ischemic accidents with the most effective med- 
ication. 
 
The ESPS 2 study began in February 1989. An interim 
analysis was done at the end of 1991. From this analysis, 
no definite conclusion was yet possible about the risk 
reductions among the four treatment arms. Practically 
same number of patients with same frequency of physio- 
logical and pathological charasteristics were included. This 
perfect randomzation is due to the good quality of the 
methodology used in the study. 
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